To reveal if coagulopathies relate to the course of COVID-19, we examined 255 patients with moderate and severe COVID-19, receiving anticoagulants and immunosuppressive drugs. Coagulopathy manifested predominantly as hypercoagulability that correlated directly with systemic inflammation, disease severity, comorbidities, and mortality risk. The prolonged clotting tests in about ¼ of cases were associated with high levels of C-reactive protein and antiphospholipid antibodies, which impeded coagulation in vitro. Contraction of blood clots was hindered in about ½ of patients, especially in severe and fatal cases, and correlated directly with prothrombotic parameters. A decrease in platelet contractility was due to moderate thrombocytopenia in combination with platelet dysfunction. Clots with impaired contraction were porous, had a low content of compressed polyhedral erythrocytes (polyhedrocytes) and an even distribution of fibrin, suggesting that the uncompacted intravital clots are more obstructive but patients could also be prone to bleeding. The absence of consumption coagulopathy suggests the predominance of local and/or regional microthrombosis rather than disseminated intravascular coagulation. The results obtained (i) confirm the importance of hemostatic disorders in COVID-19 and their relation to systemic inflammation; (ii) justify monitoring of hemostasis, including the kinetics of blood clot contraction; (iii) substantiate the active prophylaxis of thrombotic complications in COVID-19.
https://www.nature.com/articles/s41598-021-95397-6
I am not sure how this relates to my comment about microclots in COVID patients being different from other coagulopathies. The difference is noted, not so much in the formation, but the observation that COVID microclots are very resistant to normal breakdown by the body's natural enzymatic processes. This is based on the work of Dr. Pretorius who authored
this paper that brought the micro-clot issue into the public eye. The second half of this video:
also goes over the unique nature of COVID clots (seems the fibrinogen mixed with spike protein is what causes the increased resistance to breakdown). I'm not saying that HELP apheresis couldn't be helpful for pwME, as it removes clotting factors as well as bacterial toxins (makes me think of the
CBIS theory of ME), but that our micro-clots may not be as resistant to breakdown.
As I tend to do it seems i've started turning this over in my mind and looking for pattern mismatches etc.
I don't think i'm done yet but so far I've thought of a few things. Stress - tends to make people worse, this would line up with a narrowing of the blood vessels. Restless legs or body - mechanical stimulation of the muscles etc might help to shift reluctant red blood cells through the system ? PEM could simply be the result of 'running' the cells under hostile conditions ... mild to moderate lack of oxygen ? possible lack of other nutrients too ? we would expect to see increases in lactic acid under these conditions, which we do. That would explain why mild or moderates don't get PEM at 'rest', the oxygen supply is sufficient in that scenario but insufficient during exercise. Crashes and loss of stamina could either be when the toxicity in the cells becomes too much for too long of a period, or other factors amplify it, causing the cells to go on strike en masse while they regenerate / die off and regrow, this seems like a good fit for ' pacing well over time improves stamina '. The other explanation is that crashes happen when more red blood cells become deformed or however this process is occurring, which means that you feel really ill and have to rest, I suppose the question is wouldn't that turn the person a little more blue in color ? Lastly if the immune system has a hand in creating these issues or 'micro-clots', it would explain why my crashes are much worse when environmental factors in the air are also involved.
Great thought process, I have to think this is definitely a part of the ME pathology.
I would ask (
as I have before) why blood cells become deformed. Is deformity a genetic or epigenetic condition such as sickle cell or spherocytosis? Deformed blood cells cannot transport oxidant. Are died-off cells, like spherocytosis, become waste (micro clots) that lingers and clots blood vessels? “The irregular shape of the red blood cells can cause the spleen to break them down faster. A normal red blood cell can live for up to 120 days, but red blood cell with hereditary spherocytosis might live for as few as 10 to 30 days.
Good question. I tend to think it is acquired through some trigger since most of us weren't born with ME and in twin studies often only one twin develops ME. Looking at the literature, it seems the deformity makes the RBC a bit flatter than usual and less flexible. The
authors of this paper theorize that this is due to the higher levels of reactive oxygen species found in RBCs of pwME.
Apparently, this isn't enough for the spleen to remove the RBCs, otherwise, we would see hemolytic anemias, increased bilirubin, and falsely deceased HbA1Cs. The authors of this paper theorize that the change in RBC
In ME, the RBCs may be completely normal, and able to deform appropriately. But what if the micro-thrombi circulating with them are sufficient to impede their passage through the smallest capillaries? This would mean the RBCs don't get damaged, but are slow.
You may be interested in this paper which describes the actual physical changes in the RBCs of pwME:
https://ashpublications.org/blood/a...rocyte-Deformability-As-a-Potential-Biomarker. So maybe it is a combo.
Also, coagulopathies tend to be associated with increase ESR and pwME have a decreased ESR. Low ESR is actually the most consistent biomarker for ME found yet (Cort has a nice
write-up here).
Interestingly, blood hyperviscosity syndromes of all types result in a low ESR. Low RBC deformability is one cause hyperviscosity:
https://www.researchgate.net/public...cosity/link/0c960531ed0dd3724f000000/download (download the free full text)
Joshua Leisk now has 40 blood samples from patients after getting a variety of vaccines and has seen the red blood cell clustering and lack of red blood cell repelling each other - also in some samples the red blood cells look very strange...not perfectly round that is. He even saw what I think might now be fibrin about 4 weeks ago in one of the first ever samples, I thought it looked very odd the first time I saw it, but now I think it looks very similair to a micro clot (the micro clot article published an image of the micro clot and the two look incredibly similair).
Blood clots with low platelets is considered a rare side-effect for both AstraZeneca and J&J vaccine, but it makes sense to question if it could make matters worse for us on a more subtle level than what would be picked up by major adverse event reporting. Logically, any inflammatory state can aggravate a clotting situation because it increases fibrinogen.
I'm in the US so I can't really comment on the AstraZeneca vaccine, but I have seen a lot of labs now done post-vaccination and it is not uncommon to see high WBCs and high CRP (sometimes even up toward 100) in the week after vaccination, slowly returning to base-line over a month. Unfortunately, haven't seen any with fibrinogen or ESR measurements, but that would be interesting to look at too.